Clinical Cancer Research publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug ...

Lung cancer prognosis tends to be better for people diagnosed in earlier stages of the disease. Once you have received a diagnosis and the type of cancer has been identified, your healthcare provider ...

Thus, Zenocutuzumab is a promising bet for the treatment of advanced non-small-cell lung cancer and pancreatic cancer with NRG1 fusion. Because it aims at deactivating proteins which are a unique ...

More people have died of lung cancer in the Channel Islands than any other type of cancer, according to a new NHS report. The National Disease Registration Service (NDRS), part of NHS England ...

Bryant Lin has been diagnosed with stage 4 lung cancer despite never smoking in his life. The oncologist, per the Stanford Medicine blog Scope, was diagnosed with non-small cell cancer — also ...

AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed ...

December 05, 2024--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC ...

IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer Based on ADRIATIC Phase III trial results which showed a 27 ...

The FDA has granted accelerated approval to zenocutuzumab, a new drug for adults with advanced non-small-cell lung cancer (NSCLC ... tiredness, rashes, infusion reactions, breathing trouble ...

If you’ve been diagnosed with non-small-cell lung cancer (NSCLC), you’ll work ... diarrhea, appetite loss, skin rash, itching, or joint pain. Palliative care for NSCLC is used to make you ...